Teleflex Acquires Innovative Technology to Reduce Biological Formation on Medical Devices

Teleflex Incorporated TFX announced it has acquired Semprus BioSciences. The acquisition includes the core Semprus Sustain™ Technology. The transaction brings to Teleflex an innovative and patented platform technology that serves as the basis for next-generation medical devices. The technology is designed to provide the benefits of reducing complications such as thrombosis and microbial adhesion over long durations. The initial focus for the technology is its use in vascular device applications, and a Semprus Sustain™ coated Peripherally Inserted Central Catheter (PICC) is currently pending 510(k) clearance from the Food and Drug Administration (FDA). Sustain™ is also pending CE Mark approval in Europe. Under the terms of the agreement, Teleflex has acquired Semprus BioSciences for an upfront payment of $30 million. Teleflex may be required to make certain additional payments based upon the achievement of certain regulatory and revenue milestones over the next several years.